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Reduced drug accumulation as a major mechanism of acquired resistance
to cisplatin in a human ovarian carcinoma cell line: circumvention studies
using novel platinum (II) and (IV) ammine/amine complexes
S.Y. Loh, P. Mistry, L.R. Kelland, G. Abel & K.R. Harrap
Drug Development Section, The Institute ofCancer Research, Belmont, Sutton, Surrey SM2 SNG, UK.
Summary Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro
in the 41M human ovarian carcinoma cell line, established from a previously untreated patient. Three
cisplatin-resistant variants were selected at approximately 2, 4 and 6-fold resistance (in terms of 50%
inhibitory concentrations), in order to study the underlying mechanisms of acquired cisplatin resistance.
Compared to the parent line, platinum accumulation following exposure to equimolar concentrations of
cisplatin was on average (across the entire concentration range) 2.9, 3.6 and 4.8-fold lower in the 41McisR2,
4lMcisR4 and 41McisR6 cell lines, respectively. Thus the difference in uptake corresponded closely with their
resistance factor in the three resistant variants. Moreover, a significant reduction in platinum accumulation
was observed as early as 5 min after exposure to cisplatin in the 41M vs 41McisR6 cell lines. Platinum
accumulation was similar in all cell lines following exposure to equitoxic concentrations (2 h IC50) of cisplatin.
Enhanced efflux of drug was not observed between the 41M and 41McisR6 cells. In addition, there was no
difference in intracellular glutathione (GSH) levels. Our previous studies have shown no indication of
metallothionein involvement and the decrease in cisplatin uptake in the 4lMcisR6 cells was reflected by a
similar reduction in DNA interstrand cross-links (ISC) formation. These results suggest that the mechanism of
acquired resistance to cisplatin in the 4lMcisR6 cell line may be predominantly due to reduced drug uptake.
The 4lMcisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of
sodium-potassium adenosine triphosphatase (Na+, K+-ATPase), suggesting that decreased cisplatin accumula-
tion in these cells is probably not regulated by alterations in their Na+, K+-ATPase levels, and Na+ potential
across the plasma membrane. Cellular accumulation of a novel class ofplatinum (IV) ammine/cyclohexylamine
dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to
cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these
compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency
over cisplatin.
Cisplatin is a widely used anticancer drug, particularly in the
treatment of human ovarian, testicular, bladder, and head
and neck cancers (Loehrer & Einhorn, 1984; Ozols & Young,
1984; Calvert et al., 1985). However, the emergence of drug
resistance in the tumour cells and the unfavourable toxicity
profile of cisplatin (primarily nephrotoxicity) still reduces its
efficacy (Ozols & Young, 1984; Hromas et al., 1987). The
second generation drug, carboplatin, although devoid of the
major toxic limitations of the parent drug (Harrap, 1985),
has a similar spectrum of antitumour activity. Hence, there is
an urgent need for developing platinum drugs which are
capable of circumventing cisplatin/carboplatin resistance.
Many studies have reported several potential biochemical
mechanisms of cisplatin resistance. They have focused on
descriptions of cross-resistance, differences in intracellular
detoxification, decreased chromatin binding, reduced DNA
damage and enhanced DNA repair mechanisms, and reduced
drug accumulation, typically between established pairs of
sensitive and acquired cisplatin-resistance variant cell lines
(for reviews see Richon & Eastman, 1986; De Graeff et al.,
1988; Andress & Howell, 1990).
A positive correlation has been observed between cisplatin
cytotoxicity and accumulation in tumour cells (Eichholtz-
Wirth & Hietel, 1986; Metcalfe et al., 1986). Many studies
have implicated a platinum accumulation defect as an impor-
tant mechanism of cisplatin resistance in both murine
(Hromas et al., 1987; Kraker & Moore, 1988) and human
carcinoma cell lines (Teicher et al., 1987; Andrews et al.,
1988; Mann et al., 1990). Moreover, this may occur at an
early stage during development of cisplatin resistance (An-
drews et al., 1988; Andrews & Howell, 1990; Andrews et al.,
1990). It should be noted, however, that some cell lines with
cisplatin resistance do not show any difference in accumula-
tion (e.g., GLC4-CDDP human small cell lung Hospers et al.,
1988). The exact mechanism of cisplatin transport into cells is
unknown. It has been postulated that cisplatin enters cells by
passive diffusion. However, studies have shown that cisplatin
accumulation can be modulated by various treatments which
suggests that transport mechanisms other than simple passive
diffusion may be involved (Andrews & Howell, 1990).
Cellular resistance may either be present at the onset of
treatment (intrinsic) or develop after an initial response
(acquired). Our platinum-based drug discovery program, is
aimed at developing a new generation of platinum analogues,
capable of circumventing both intrinsic and acquired resist-
ance to cisplatin and to broaden its clinical spectrum of
activity. To assist in these objectives, we are establishing in
vitro and in vivo screening models exhibiting intrinsic and
acquired resistance to cisplatin, and determining mechanisms
of resistance in these models. We have selected a sensitive
human ovarian carcinoma cell line, 41M, which was estab-
lished from a previously untreated patient, and developed
sublines with varying degrees of resistance to cisplatin. We
have examined differences in cisplatin accumulation, drug
efflux, and GSH levels in these cell lines. As two previous
reports have suggested a role for the membrane-bound Na+,
K+-ATPase in cisplatin uptake (Kawai et al., 1987; Andrews
et al., 1991) we determined the cytotoxicity of ouabain, a
postulated specific inhibitor of the Na+, K+-ATPase, in these
cell lines. In addition, the cytotoxicity of a novel class of
platinum (IV) ammine/cyclohexylamine dicarboxylates and a
Pt (II) complex, JM118 (cis-amminedichloro (cyclohexylamine)
platinum (II)), which exhibit dramatic and selective cytotoxic
activity in cisplatin-refractory cell lines (Harrap et al., 1991;
Kelland et al., 1992a), has been determined. The accumula-
tion of these complexes in the sensitive and resistant cell lines
was also compared with that of cisplatin.
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Materials and methods
Drugs and chemicals
All platinum-containing agents were synthesized by and
obtained from the Johnson Matthey Technology Centre
(Reading, Berkshire, UK). The procedures for the synthesis
ofthese drugs have been described recently (Giandomenico et
al., 1991). The structures of the platinum complexes and the
generalised structure of platinum (IV) ammine/cyclohexyl-
amine dicarboxylates used in this study are shown in Figure
1. Ouabain octahydrate and all other chemicals were pur-
chased from Sigma Chemicals UK Ltd.
Cell lines
The human ovarian carcinoma cell line, 41M, used in this
study was derived from a previously untreated patient.
Details of its biological properties have been described
previously (Hills et al., 1989). This cell line was made resist-
ant to cisplatin by continuously exposing cells to increasing
concentrations of drug (up to a maximum of 1 tLM) over a
15-month period. Cell lines (4lMcisR2, 4IMcisR4,
4IMcisR6) with approximately 2-fold, 4-fold and 6-fold
degrees of resistance respectively, were generated. Cells were
grown as monolayers in Dulbecco's modified Eagle's medium
(DMEM) augmented to contain 10% fetal calf serum
(Imperial Laboratories, Andover, UK), 50 lAg ml-' gen-
tamicin, 2.5 fig ml-' amphotericin B, 2 mM L-glutamine,
10fg ml-' insulin, and 0.5 tg ml-' hydrocortisone in a 10%
C02, 90% air atmosphere. Cells were periodically checked
and were found to be free of mycoplasma.
Assessment ofcytotoxicity
All platinum agents were dissolved immediately before use in
either 0.9% saline (at 500 LM for cisplatin, JM118, and
JM216) or absolute ethanol (at 5 mM for the other platinum
(IV) dicarboxylates). The final concentration of ethanol
(0.5%) in the medium had no growth-inhibitory effect on the
cells. Ouabain was dissolved in sterile water at 1 mM.
Cytotoxicity was assessed as described recently (Mistry et
al., 1991; Kelland et al., 1992a) using the sulforhodamine B
(SRB) assay. Briefly, single viable cells were seeded into
96-well microtitre plates (1 x 104cells/well in 200yl of
growth medium). After an overnight attachment period, cells
in quadruplicate wells were exposed to various concentra-
tions of agents for either 2 or 96 h. After a 2 h exposure
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Figure 1 Structures of the platinum complexes studied and the
generalised structure of the platinum (IV) ammine/cylcohexyl-
amine dicarboxylates, JM216 (R = CH3); JM221 (R = nC3H7);
JM274 (R = nC4H9); JM280 (R = nC9H,9).
period, the cells were consecutively washed with 200 il of
phosphate buffered saline, pH 7.2 (PBS) and medium at
37°C. Fresh medium was then added to the cells and the
plates were further incubated for 96h. Basic amino acid
content/well was analysed using 0.4% SRB in 1% acetic acid.
Intracellular platinum accumulation
Platinum drugs were added to approximately 1-4 x 106 ex-
ponentially growing cells either at various concentrations for
2 h or at a single concentration for various times up to
120 min. Immediately after the drug exposure period, the
medium was aspirated and the cells were washed with
3 x 25 ml of ice-cold PBS. Subsequently, the cells were
scraped, harvested in 0.5 ml PBS and sonicated (Soniprep
150; Fisons, Loughborough, UK) at 4°C. The intracellular
platinum content was determined using flameless atomic
absorption spectrometry (Perkin Elmer 1lOOB and HGA 700,
Beaconsfield, UK). Under these conditions the detection limit
was 5-1Ong platinum per ml. Recovery was approximately
90%. Protein content was assayed according to Lowry et al.
(1951) using a 50f1l aliquot of cell sonicate which had been
digested overnight in 2009A1 of 1.0 N sodium hydroxide at
37°C. Cellular platinum levels were expressed as nmol of
platinum/mg of protein.
Drug efflux studies
The loss of cellular platinum over a 2 h period was examined
after preincubating the 41M and 41McisR6 cells (1-4 x 106)
with 50 and 200jAM cisplatin, respectively for 30 min. At
these incubation concentrations, cellular platinum levels at
30 min were similar in the two cell lines. In another set of
experiments, parent and resistant variant were preincubated
for 120 min in 50tLM cisplatin. At the end of the drug-
loading period, the medium was aspirated and the mono-
layers were washed with 2 x 8 ml of drug-free medium. The
washing procedure time of 90 s was added on to the efflux
time. Cells were then incubated further in fresh medium for
various times up to 120 min. Efflux was terminated by
aspirating the medium and washing the cells with 3 x 25 ml
ice-cold PBS. Cells were then processed and analysed for
platinum and protein as described above.
GSH assay
The total GSH content of the cell lines were determined by
an enzymatic assay utilising gluthathione reductase as de-
scribed recently (Mistry et al., 1991). The GSH content was
expressed as nmol per 106 cells or per mg protein.
Statistical analysis
All statistical analysis was performed using the Student's
t-test.
Results
Although none of the lines have been cloned, the acquired
resistant cell lines appeared identical to the parent line in
terms of morphology under phase-contrast microscopy and
the population doubling time (27 h). The parent line had
been passaged in vitro around 30 times before the generation
of resistance was begun. As described previously (Hills et al.,
1989) 41M cells appeared as homogeneous small round cells
within tightly adherent colonies. In addition, there were no
significant differences in cell volume which was determined
using a coulter counter.
Cytotoxicity ofplatinum complexes
The three cisplatin-resistant variants of the 41M cell line used
in the accumulation studies were selected at approximately 2,
4, and 6-fold resistant, as determined by the SRB assay, after
a 96 h continuous drug exposure. The resistance factors afterMECHANISM OF CISPLATIN ACQUIRED-RESISTANCE IN HUMAN OVARIAN CELLS 1111
2 h drug exposure were slightly lower (Table I). Resistance
appeared to be stable for at least 6 months without further
maintenance doses of cisplatin. The sensitivity profile of 41M
and 4lMcisR6 cells to four novel platinum (IV) ammine/
cyclohexylamine dicarboxylates and to a platinum (II) com-
plex (JM1 18) after a 2 and 96 h continuous exposure, is
shown in Table II. The four platinum (IV) compounds had
varying numbers of total carbon atoms (4-20) in their axial
chains; JM216 (R = CH3), JM221 (R = nC3H7), JM274 (R
= C4H9), and JM280 (R = nC9Hl9). Enhanced cytotoxicity of
these platinum (IV) complexes was observed as the number
of axial carbon atoms increased from four to ten. The com-
pound containing the longest axial chain, JM280 (with 20-
carbon atoms), however, retained an ICs similar to the
10-carbon complex, JM274. This study correlated with our
previous findings in six human ovarian carcinoma cell lines
(Kelland et al., 1992a). The cross-resistance profile of 41-
McisR6 vs the parent line of these platinum (IV) agents is
shown in Figure 2. The dicarboxylate compounds were able
to circumvent completely resistance to cisplatin in the 41-
McisR6 cell line (resistance factor < 1.5).
Cytotoxicity ofouabain
The ICs for ouabain after a 96 h continuous drug exposure
was 0.084 and 0.043 (mean; n = 2) in the 41M and 41McisR6
cell lines, respectively. Hence, the cisplatin acquired-resistant
cell line, 4IMcisR6, which was approximately 6-fold resistant
to cisplatin, was not cross-resistant to ouabain (resistance
factor = 0.6).
Cisplatin accumulation
To examine whether the basis for the acquired resistance to
cisplatin was related to alterations in drug accumulation, we
have determined the intracellular platinum levels immediately
after a 2 h exposure to various concentrations of cisplatin.
Although the maximum concentration of drug was higher
than the ICs concentrations (2 h exposure) we did not
observe any cellular detachment during the washing pro-
cedure and, moreover, similar levels of protein were obtained
to that at lower cisplatin concentrations. Figure 3 shows that
platinum accumulation in the parent and three acquired-
resistant variants was a linear function ofcisplatin concentra-
tion up to at least 100 gM. In fact, lack of saturation of
platinum accumulation was observed up to 500 tAM cisplatin
Table I Relationship
accumulation in sensitive
between cytotoxicity and cisplatin
parent and cisplatin-acquired resistant
variants
Pt accumulation
(pmol Pt/mg protein)
2 h IC50
Cell line CuM) RF 2 h IC50a 25tIMb
41M 3.0 0.9 - 30 278(1.0)
41McisR2 7.3 ± 2.6 2.4 ± 0.9 29 85(3.2)
41McisR4 8.8 ± 0.3 2.9 ± 0.7 23 70(4.0)
41McisR6 9.2 ± 3.3 3.1 ± 0.5 32 50(5.6)
RF = resistance factor (ICm cisR/IC5n parent). aValues were
obtained from accumulation curves (Figure 3). bValues represent
mean of three determinations. Numbers in parentheses represent
-fold reduction in platinum accumulation relative to the parent line.
6-
5.
.I. 4-
4)
Co
(>
3.-
CU)
CD a) 2-
cr
n
o = 2 hour
* = 96 hour
.K FIl
CDDP JM JM JM
118 216 221
Platinum agent
JM JM
274 280
Figure 2 Cross-resistance profile of 2 h (open) and 96 h (shaded)
of 41M versus 41McisR6 to cisplatin, JM118, JM216 (R = CHA
JM221 (R = nC3HA), JM274 (R = nC4H9) and JM280 (R =
nC9Hl9). Resistance factor = IC50 cisR line/IC50 parent line; val-
ues are mean from two experiments.
concentration in all cell lines (data not shown). At each
exposure concentration, platinum levels were reduced signi-
ficantly (P = 0.01) in the acquired-resistant variants when
compared with the parent line. However, there was no
significant difference at any cisplatin concentration in
platinum levels between the 2- and 4-fold resistant lines.
Across the range of concentrations used, intracellular
platinum levels when compared to the parent line, were an
average (across the entire concentration range) of 2.9 ± 0.6,
3.6 ± 1.0, and 4.8 ± 0.6-fold lower in the 41McisR2,
4IMcisR4, and 4lMcisR6 variants, respectively. Hence, the
-fold reduction (calculated only for the 25 tiM dose-point) in
platinum accumulation was similar to the resistance factor in
each cell line (Table I). In contrast, the intracellular platinum
levels after exposure to equitoxic concentrations of cisplatin
were found to be similar for all cell lines (Table I).
Figure 4 shows that following exposure to 100 jM cis-
platin, platinum accumulation was linear over 60 min (r =
0.982) for 41M and over 120 min (r = 0.992) for 41McisR6.
Additionally, a significant reduction in accumulation in the
acquired-resistant variant was observed at the earliest time
point of 5 min. The reduction ranged from 1.5-2.5-fold over
the 120 min exposure period and was statistically significant
at all times (P<0.01).
The time course for platinum efflux into drug-free medium
was determined in 41M and 41McisR6 cell lines following a
30 min loading period at 50 and 200 jAM cisplatin (Figure 5a)
and 120min at 50 gM cisplatin (Figure Sb). No significant
diference in efflux of platinum was observed between the cell
lines (P>0.5 at each time point investigated). The amount of
platinum which escaped from both cell lines (20-30%) was
independent of whether the cells were loaded with 50 or
200 jiM cisplatin, or whether the cells were loaded for 30 or
120 min.
Accumulation ofnovelplatinum (IV) complexes
To determine if enhanced cellular accumulation contributed
to the lack of cross-resistance of platinum (II and IV) com-
Table II In vitro sensitivity profile of 41M and 4lMcisR6 cells after 2 and
96 h exposure to platinum drugs
Platinum 2 h IC5o (iM) 96 h IC50 (gM)
drug R 41M 41McisR6 41M 4JMcisR6
Cisplatin - 2.9 0.8 8.5 0.1 0.2 0.01 1.3 0.07
JM118 - 2.4±0.5 1.1 ±0.5 0.2±0.02 0.1 ±0.01
JM216 nCH3 19 6.4 13.5 2.1 0.8 0.06 0.4 0.05
JM221 nC3H7 1.2 ± 0.4 1.0 ± 0.1 0.03 ± 0.02 0.02 ± 0.004
JM274 nC4H9 0.8 ± 0.2 0.4 ± 0.2 0.01 0.005
JM280 nC9Hlg 1.1 0.5 0.6 0.3 0.01 0.011
Values = mean ± s.d. in 3 experiments.
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Figure 3 Intracellular platinum accumulation immediately after a 2 h exposure to various concentrations of cisplatin in 41M (0),
41McisR2 (0), 41McisR4 (U), and 4lMcisR6 (A) cell lines. Error bars = ± s.d. of triplicate determinations of 3-4 experiments.
s.d. was less than the symbol size where not indicated.
pounds to cisplatin, we have compared their accumulation
with that of cisplatin in the 41M (Figure 6a) and 4lMcis R6
(Figure 6b) cell lines. The accumulation of all 5 platinum
compounds was significantly greater than that of cisplatin at
equimolar concentrations in the 41McisR6 cell line. More-
over, there was no significant difference in the accumulation
of these compounds between the parent and cisplatin ac-
quired-resistant cell lines. Intracellular platinum accumula-
tion in both cell lines was linear up to 25 JAM for JM221
11 A _
-
4-
0
0) 0
E
0) E 0
0
a.
0 20
(R = nC3H7), JM274 (R = nC4H9) and JM280 (R = nCgHlg),
and up to 100 JAM for cisplatin, JM118 and JM216 (R =
CH3). In addition, a positive correlation between platinum
accumulation and the number of axial carbon atoms (up to a
total of 10) was observed at all drug concentrations in both
cell lines. However, platinum accumulation following expo-
sure to JM280 with 20 axial carbon atoms was similar to that
of JM118 and JM216 (with 0 and 4 axial carbon atoms,
respectively).
Time (min)
Figure 4 Intracellular platinum accumulation after various exposure times to cisplatin in 41M (-) and 4lMcisR6 (A) cell lines.
Error bars = ± s.d. of triplicate determinations in two experiments. s.d. was less than the symbol size where not indicated.
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Table Ill GSH levels in 41M and cisplatin acquired resistant
variants
GSH concentration
Cell line nmol/106 cells nmol/mg protein
41M 18.2 3.3 28.9±4.8
41McisR2 12.5 ± 4.8 28.7 + 6.3
4lMcisR4 27.2 ± 14.3 27.9 ± 6.7
41McisR6 21.8 9.7 26.4 6.1
Values = mean ± s.d. of duplicate determinations in 3-4
experiments.
that reduced drug accumulation may play a major role in the
mechanism of acquired resistance to cisplatin in these cell
lines. The reduced drug accumulation appears to be caused
by reduced uptake and not increased efflux since no
significant differences in the loss of platinum was observed
between the 41M and 4lMcisR6 cell lines. These results
correspond to the findings ofTeicher et al. (1987) and Waud
(1987). In contrast, Mann et al. (1990) reported that the rate
constant for rapid efflux (within the first 5 min after a 10min
drug loading period) was 53% higher in resistant compared
to parent 2008 human ovarian carcinoma cells.
The precise mechanism(s) by which cisplatin enters cells is
unknown and both passive diffussion and carrier mediated
transport have been implicated (for review see Andrews &
Howell, 1990). We found that cisplatin accumulation was not
saturable up to 500gM which agrees with other studies in a
variety of tissue types (Eichholtz-Wirth & Hietel, 1986; Hec-
quet et al., 1986; Hromas et al., 1987; Andrews et al., 1988).
Although this suggests that transport of cisplatin may occur
Figure 5 Loss of cisplatin over a 120 min period from 41M (0)
and 41McisR6 (A) cell lines preincubated with cisplatin. 41M
and 41McisR6 cells were preincubated in 50 and 200ylM cisplatin,
respectively for 30 min a, and in 50 gM cisplatin for 120 min b. At
the end of the preincubation period, cells were washed and
incubated in drug-free medium for various times before determin-
ing the retained intracellular platinum levels as described in
materials and methods. Error bars= s.d. of triplicate deter-
minations in two experiments.
GSH concentrations
Intracellular GSH was measured to determine if elevated
levels contributed to the resistant phenotype as has been
reported elsewhere (Arrick & Nathan, 1984; Green et al.,
1984; Andrews et al., 1985; Louie et al., 1985). There was no
significant difference (P>0.05) in GSH concentration be-
tween parent and acquired-resistant variants, in terms of
either cell numbers or protein content (Table III).
Discussion
Both intrinsic and acquired resistance to cisplatin limit the
clinical utility of this valuable anticancer drug. Many studies
have shown that decreased accumulation of cisplatin is an
important factor in the in vitro and in vivo acquisition of
resistance to this antitumour compound (Hromas et al., 1986;
Richon & Eastman, 1986; Richon et al., 1987; Teicher et al.,
1987; Kraker & Moore, 1988; Andrews et al., 1990). In the
present study we examined the role of reduced drug accu-
mulation as a possible mechanism of resistance to cisplatin in
the acquired-resistant variants of a sensitive human ovarian
carcinoma cell line (41M), which was established from a
previously untreated patient. Intracellular platinum accumu-
lation was significantly reduced in the acquired-resistant
variants compared to the parent line. Furthermore, the
several-fold reductions following exposure to equimolar con-
centrations of cisplatin closely paralleled the resistance fac-
tors to cisplatin. However, at equitoxic concentrations of
cisplatin, similar amounts of platinum were accumulated in
the parent and the resistant sublines. These results suggest
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primarily by passive diffusion, the involvement of carrier
mediated transport cannot be ruled out. Several reports have
shown that cisplatin accumulation can be modulated by
various treatments (e.g., Kikuchi et al., 1990; Morikage et al.,
1991). In addition, specific changes in plasma membrane
proteins have been reported in association with reduced cis-
platin accumulation in resistant cells (Bernal et al., 1990;
Kawai et al., 1990). We are currently evaluating whether
alterations in cell membranes are responsible for the reduced
drug uptake in the acquired resistant 4lMcisR6 cell line.
Recently both Kawai et al. (1987) and Andrews et al. (1991)
have postulated a central role for Na+,K+-ATPase in cis-
platin accumulation. This enzyme regulates the transmem-
brane Na+ gradients which in turn was found to partially
regulate cisplatin accumulation in the 2008 human ovarian
cell line (Andrews et al., 1991). However, our results showed
a lack of cross-resistance to ouabain, a postulated specific
inhibitor of Na+,K+-ATPase, in the 4lMcisR6 cell line. This
suggests that reduced drug accumulation in these cells is
probably not regulated by an alteration in their Na+,K+-
ATPase levels.
Ammine/amine platinum (IV) dicarboxylates represent a
novel class of antitumour complex which exhibit selective
activity in cisplatin-refractory cell lines (Harrap et al., 1991;
Kelland et al., 1992a). Some of these dicarboxylates, es-
pecially those containing a total of 8 or more carbon atoms
in their axial ligands, possess dramatic in vitro cytotoxic
properties in human ovarian carcinoma cell lines (Kelland et
al., 1992a). Therefore, these compounds may provide a lead
to the development of platinum drugs capable of circumvent-
ing cisplatin resistance. In this study we have compared the
cytotoxicity of cisplatin with that of a platinum (II) complex
(JM118) and 4 platinum (IV) ammine/cyclohexylamine dicar-
boxylates in the 41M and 4lMcisR6 cell lines. The dicarboxy-
late complexes examined contained a range of 4-20 total
number of axial carbon atoms. Interestingly, all these com-
plexes (including JM118) were capable of circumventing ac-
quired resistance to cisplatin in the 41McisR6 cell line and
some were more potent than cisplatin in the parent cell line.
To establish the mechanistic basis for their increased potency
and lack of cross-resistance to cisplatin, we have compared
the accumulation of these complexes with that of cisplatin in
the sensitive and resistant cells. Our results indicated that the
lack of cross-resistance may be attributable to the fact that
the resistant cells were unable to retard the accumulation of
these complexes. This may be related to their increased lipo-
philicity since accumulation of these dicarboxylates increased
with increasing number of axial carbon atoms up to a total
of 10. For example, while solubility in water (at 25°C)
decreased along the series cisplatin (1183 gg ml 1), JM118
(216pg ml-'), JM216 (170 ggml-'), and JM221 (75 JLg ml-'),
solubility in octanol increased from 7.8pg ml-' for cisplatin,
to values of 37 for JM18, 54 for JM216, and 1317 for
JM221. However, JM280, one of the most potent compounds
with 20 axial carbon atoms, showed similar levels of accu-
mulation to JM216, which contained only 4 axial carbon
atoms.
Other factors involved in the mechanism of resistance such
as intracellular detoxification through interaction with cel-
lular thiols, or reduced Pt-DNA adduct formation and
enhanced repair of DNA lesions must also be taken into
account. Differences in GSH levels between sensitive and
resistant cells cannot be implicated here, since none were
found (Table III). Whether reduced GSH contributes the
acquired-resistant phenotype appears to be dependent upon
cell type since some show differences between sensitive and
resistant lines (e.g. Green et al., 1984; Louie et al., 1985) and
others do not (e.g. Andrews et al., 1985). We have reported
previously that there was no direct involvement of intracel-
lular metallothioneins in the mechanism of resistance, as
indicated by the sensitivity of the cell lines to cadmium
chloride (Loh et al., 1991). Furthermore, the reduction in
cisplatin uptake in 4lMcisR6 cells was reflected by a similar
reduction in DNA interstrand crosslink formation, as mea-
sured by alkaline filter elution (Loh et al., 1991; Kelland et
al., 1992b).
In summary, reduced drug accumulation plays a major
role in the mechanism of cisplatin acquired-resistance in the
4lMcisR6 cell line. Moreover, since reduced drug accumula-
tion was observed in ancestors of this cell line with lower
levels of resistance, it appears that this mechanism is involved
at an early stage in the development of cisplatin resistance in
these cells. Identification of alterations in plasma membranes
of these cells could provide new strategies to circumvent
cisplatin resistance caused by reduced drug accumulation. We
have also shown, through use of the novel platinum (IV)
ammine/cyclohexylamine dicarboxylate complexes, that resis-
tance to cisplatin caused by reduced drug accumulation may
be largely overcome by increasing the lipophilicity of the
platinum agent. Such compounds could provide a lead to
new 'third-generation' platinum containing agents to combat
cancers currently resistant to cisplatin and which might
exhibit a broader spectrum of antitumour activity.
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